Skip to main content
ANIX
NASDAQ Life Sciences

Anixa Biosciences Reports Positive Survival, Strong Safety in Lira-Cel Ovarian Cancer CAR-T Phase 1 Trial

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.99
Mkt Cap
$100.584M
52W Low
$2.44
52W High
$5.457
52W Position info
23% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ANIX sits 23% above its 52-week low of $2.44.

Summary

Anixa Biosciences announced updated positive survival observations from its ongoing Phase 1 trial of Lira-Cel, its CAR-T therapy for ovarian cancer. Crucially, the company also reported no dose-limiting toxicities, ICANS, or significant cytokine release syndrome (CRS) in the first three dose cohorts. For a small biotech company, these positive early-stage clinical results, particularly the strong safety profile, are highly material as they significantly de-risk the development of this novel therapy. This data provides a strong foundation for the program's future, suggesting both potential efficacy and good tolerability. Investors will closely monitor the continued progress of the Lira-Cel trial and anticipate further data readouts and potential advancement to later clinical stages.

At the time of this announcement, ANIX was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.6M. The 52-week trading range was $2.44 to $5.46. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ANIX - Latest Insights

ANIX
Oct 26, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.61 info
Change: -$0.380 (-13%) info
Market Cap: $91.081M info
ANIX
Oct 05, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.61 info
Change: -$0.380 (-13%) info
Market Cap: $91.081M info
ANIX
Jul 14, 2026, 8:33 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $2.61 info
Change: -$0.412 (-14%) info
Market Cap: $91.081M info
ANIX
Jun 29, 2026, 8:45 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.79
Real-time Price: $2.61 info
Change: -$0.1832 (-7%) info
Market Cap: $91.081M info
ANIX
Jun 10, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.36
Real-time Price: $2.61 info
Change: +$0.250 (+11%) info
Market Cap: $91.081M info